How cerebellum brain chemicals affect keeping or letting go of fearful memories

The role of cerebellar endocannabinoids in the reconsolidation and extinction of fear memory

NIH-funded research Southeast Louisiana Veterans Health Care · NIH-11213978

This work looks at whether a natural brain chemical in the cerebellum can help weaken traumatic fear memories for people with PTSD, including veterans.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionSoutheast Louisiana Veterans Health Care NIH-funded
Lab location1 site (New Orleans, United States)
Project IDNIH-11213978 on NIH RePORTER

What this research studies

You should know that researchers are studying how the cerebellum and a natural signaling molecule called 2-AG influence whether fearful memories stick or fade. Most experiments use lab models (animals) and lab-based methods to change 2-AG levels or related enzymes in the cerebellum and then measure fear extinction and reconsolidation after memory recall. The team compares approaches that promote extinction (learning safety) with those that make a memory temporarily fragile after recall, using drugs or molecular tools. Results aim to point to biological targets that could be tested later in people with persistent fear from trauma.

Who could benefit from this research

Good fit: People with PTSD—especially veterans—with ongoing, fear-based symptoms that have not fully responded to current treatments would be the most likely candidates for future therapies based on this work.

Not a fit: Patients whose problems are driven mainly by non–fear mechanisms (for example, primarily mood disorders, cognitive impairment, or active substance dependence) may not benefit directly from these findings.

Why it matters

Potential benefit: If successful, this could point to new drug or therapeutic targets to reduce persistent fear memories in PTSD.

How similar studies have performed: Preclinical animal studies have shown that changing endocannabinoid signaling can alter fear extinction and reconsolidation, but human trials translating these findings are limited.

Where this research is happening

New Orleans, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anxiety Disorders
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.